Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,331 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms, Hematopoietic Clear all
Completed Not applicable Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

NCT00453206
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 15, 2026, 11:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR

NCT01611298
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
Tetanus
Biological
Lead sponsor
Robert Krance
Other
Eligibility
3 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 15, 2026, 11:16 AM EDT
Terminated Phase 2 Interventional Results available

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

NCT02648932
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Haplo-Cord Transplant, Matched Unrelated Donor Transplant
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

NCT03224507
View directory record Official record
Conditions
Multiple Myeloma
Interventions
KRdD followed by auto-HCT, KRdD only
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 15, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional

A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota

NCT07291011
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Electronic Health Record Review, Mindfulness Relaxation, Questionnaire Administration
Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Terminated Phase 2 Interventional

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

NCT00009984
View directory record Official record
Conditions
Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
fludarabine phosphate, thalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 15, 2026, 11:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

NCT06192875
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2035
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

NCT00104065
View directory record Official record
Conditions
Stomatitis
Interventions
CG53135-05, velafermin
Drug
Lead sponsor
CuraGen Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

NCT02210065
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 15, 2026, 11:16 AM EDT
Completed No phase listed Observational

Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors

NCT02301065
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 15, 2026, 11:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses

NCT04960787
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Educational Intervention, Patient Navigation, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
264
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Antioch, California + 211 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

NCT00317785
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2010 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

NCT00185757
View directory record Official record
Conditions
Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Cytokine Induced Killer Cells
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person

NCT07141407
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Supportive Care, Telephone-Based Intervention, Survey Administration, Educational Intervention
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Everett, Washington • Mount Vernon, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional

Massage Impact on Sleep in Pediatric Oncology

NCT06892158
View directory record Official record
Conditions
Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Massage therapy, Standard of care
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Not applicable Interventional Results available

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

NCT02331134
View directory record Official record
Conditions
Malignant Melanoma, Head and Neck Cancer
Interventions
Filgrastim
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

NCT00553098
View directory record Official record
Conditions
Immunodeficiency Syndrome, Non-Cancer Diagnosis
Interventions
Alemtuzumab, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Oakland, California • Cleveland, Ohio • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 15, 2026, 11:16 AM EDT
Terminated Phase 2 Interventional Results available

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT01532635
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
Radiation · Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 15, 2026, 11:16 AM EDT
Terminated Phase 1 Interventional

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

NCT05065047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Meloxicam vs Placebo for Mobilization

NCT02003625
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
Interventions
GCSF, meloxicam, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

NCT00321932
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 15, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

NCT00697684
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Non Hodgkin's Lymphoma, Hodgkins Disease, Relapsed Refractory Multiple Myeloma
Interventions
Antithymocyte Globulin, Clofarabine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 15, 2026, 11:16 AM EDT